Trial Profile
A Multicenter, Randomized Phase II Study Evaluating the Feasibility and Activity of Two Different Combinations of Docetaxel and Gemcitabine and of Cisplatin/Gemcitabine Followed by Docetaxel as First Line Therapy for Locally Advanced Unresectable or Metastatic Non-Small Cell Lung Cancer.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 11 Feb 2010
Price :
$35
*
At a glance
- Drugs Cisplatin (Primary) ; Docetaxel (Primary) ; Gemcitabine (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 07 Jul 2009 Planned end date (Apr 2005) added as reported by ClinicalTrials.gov.
- 07 Jul 2009 Planned end date (Apr 2005) added as reported by ClinicalTrials.gov.
- 13 Mar 2008 Status changed from in progress to completed as reported by ClinicalTrials.gov.